Jeremy Sohn

Jeremy joined Novartis in 2015 as VP, Head of Digital Business Development & Licensing reporting to the Chief Digital Officer and supporting Novartis’ digital innovation programs cross-divisionally and globally. While serving in this role, Jeremy was also appointed ad-interim Global Head of Commercial Digital Medicines (2017), overseeing the digital medicine leads within the global franchises and regions, and, Global Head of Digital Development (2016), leading Novartis’ clinical trial innovation efforts within Global Drug Development.

Jeremy is a serial software entrepreneur with more than 20 years of experience founding and managing healthcare and technology companies. Jeremy is a Board Member and Advisor to a number of digital health companies, including Pear Therapeutics, Science 37, MintHealth, NovaSignal, and COTA. Prior to Novartis, Jeremy was Managing Director at MPM Capital where he led the firm’s digital-health investment strategy. At MPM, Jeremy founded two companies, CentrosHealth (acquired by Clinical Ink) and TriNetX. In 2011, Jeremy co-founded GrapeVine, a software company that optimizes how organizations connect with their target communities. From 2007-2011, Jeremy was COO and VP, Strategy & Corporate Development for North Plains Systems, where he led the company’s growth and eventual sale to Accel-KKR. In 2000, he co-founded an open-source operating system company, Wasabi Systems.